AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21031343 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with fixed dose of 4 mg rosiglitazone plus 500 mg metformin (RSG+MET group, n = 70)
Number of subjects: 140
Study 21031343 — intervention group
Group type: COMPARATOR
Intervention: Half-maximum dose of metformin monotherapy (MET group, n = 70)
Number of subjects: 140
Study 19558782 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterograde intracoronary artery (ICA) delivery of 100 million BMMNC
Number of subjects: 30
Study 19558782 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde intracoronary vein (ICV) delivery of 100 million BMMNC
Number of subjects: 30
Study 19558782 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 16822278 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem with voriconazole pretreatment
Number of subjects: 10
Study 16822278 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem without voriconazole pretreatment
Number of subjects: 10
Study 11040881 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 23303
Study 8879373 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (sequential 5‐fluorouracil/leucovorin combined with etoposide or FLv for elderly/poor performance patients)
Number of subjects: 90
Study 8879373 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 90
Study 8879373 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 90
Study 2049700 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin use among diagnosed diabetics
Number of subjects: 100
Study 2049700 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence rate by gender
Number of subjects: 100
Study 6362699 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.25 mg
Number of subjects: 0
Study 6362699 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.5 mg
Number of subjects: 0
Study 6362699 — intervention group
Group type: COMPARATOR
Intervention: Nitrazepam 5.0 mg
Number of subjects: 0
Study 31172740 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-qubit randomized benchmarking (RB) with all-to-all gate connectivity
Number of subjects: 3
Study 31172740 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-qubit randomized benchmarking (RB) with linear gate connectivity
Number of subjects: 3
Study 31172740 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-qubit randomized benchmarking (RB) with coherent errors introduced
Number of subjects: 3
Study 31172740 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous one- and two-qubit RB
Number of subjects: 3
Study 29275334 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 52
Study 29275334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 26443019 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg zinc tablets daily for 12 months
Number of subjects: 40
Study 26443019 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets daily for 12 months
Number of subjects: 40
Study 24698202 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency volumetric thermal ablation (RFVTA)
Number of subjects: 0
Study 24698202 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic myomectomy (LM)
Number of subjects: 0
Study 24698202 — intervention group
Group type: EXPERIMENTAL
Intervention: RFVTA
Number of subjects: 0
Study 24698202 — intervention group
Group type: COMPARATOR
Intervention: LM
Number of subjects: 0
Study 22152099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density negative ion (HDNI) treatment
Number of subjects: 0
Study 22152099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20546266 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication possession ratio (MPR)
Number of subjects: 526
Study 20546266 — intervention group
Group type: EXPERIMENTAL
Intervention: Morisky Medication-taking Scale
Number of subjects: 526
Study 20546266 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-taking item of the Summary of Diabetes Self-Care Activities (SDSCA)
Number of subjects: 526
Study 20546266 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report adherence measures
Number of subjects: 526
Study 18056491 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (20 digits)
Number of subjects: 30
Study 18056491 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (15 digits)
Number of subjects: 30
Study 18056491 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic group (29 digits)
Number of subjects: 30
Study 18056491 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic corticosteroid group (19 digits)
Number of subjects: 30
Study 18056491 — intervention group
Group type: COMPARATOR
Intervention: Diabetic placebo group (15 digits)
Number of subjects: 30
Study 16211735 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.2 mg kg[-1])
Number of subjects: 0
Study 16211735 — intervention group
Group type: COMPARATOR
Intervention: Propofol (2 mg kg[-1])
Number of subjects: 0
Study 11945098 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 1200 mg/day
Number of subjects: 252
Study 11945098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 10096369 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 3040
Study 10096369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040
Study 8773063 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid 6.5 mg/kg
Number of subjects: 78
Study 8773063 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 10 mg/kg
Number of subjects: 78
Study 8773063 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 7 mg/kg
Number of subjects: 78
Study 1689173 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (10 mg/day)
Number of subjects: 57
Study 1689173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 31639150 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficiency on-line hemodiafiltration (HDF)
Number of subjects: 113
Study 31639150 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-flux hemodialysis (HD)
Number of subjects: 113
Study 28505292 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Auricular Point Acupressure (APA)
Number of subjects: 29
Study 28505292 — intervention group
Group type: COMPARATOR
Intervention: Sham Auricular Point Acupressure (APA)
Number of subjects: 29
Study 26549134 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral infraorbital and infratrochlear nerve blocks with 10 mL of 0.25% levobupivacaine (Group LB)
Number of subjects: 40
Study 26549134 — intervention group
Group type: COMPARATOR
Intervention: Control group (isotonic saline)
Number of subjects: 40
Study 24430534 — intervention group
Group type: EXPERIMENTAL
Intervention: rilpivirine 25 mg once daily
Number of subjects: 690
Study 24430534 — intervention group
Group type: COMPARATOR
Intervention: efavirenz 600 mg once daily
Number of subjects: 690
Study 22341989 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session group
Number of subjects: 48
Study 22341989 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-session group
Number of subjects: 48
Study 21775113 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription omega-3-acid ethyl esters (POM3)
Number of subjects: 19
Study 21775113 — intervention group
Group type: COMPARATOR
Intervention: Corn oil
Number of subjects: 19
Study 18040542 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical holistic medicine (CHM)
Number of subjects: 0
Study 18040542 — intervention group
Group type: COMPARATOR
Intervention: Standard psychiatric treatment (TAU)
Number of subjects: 0
Study 16221265 — intervention group
Group type: COMPARATOR
Intervention: One extrastimulus
Number of subjects: 121
Study 16221265 — intervention group
Group type: COMPARATOR
Intervention: Two extrastimuli
Number of subjects: 121
Study 16221265 — intervention group
Group type: COMPARATOR
Intervention: Follow-up
Number of subjects: 121
Study 11897585 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of artemisinin daily for 5 days (group A; n = 40)
Number of subjects: 77
Study 11897585 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin at a dose of 100 mg per day for 2 days, increased to 250 mg per day for 2 consecutive days, and 500 mg on the fifth day (group B; n = 37)
Number of subjects: 77
Study 11897585 — intervention group
Group type: COMPARATOR
Intervention: Group A (500 mg daily for 5 days)
Number of subjects: 77
Study 11897585 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (escalating doses of artemisinin)
Number of subjects: 77
Study 11897585 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups on day 5
Number of subjects: 77
Study 10631689 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (dose-intensive) therapy for breast cancer
Number of subjects: 0
Study 7498206 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg
Number of subjects: 27
Study 7498206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 1702552 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran + Acetylsalicylic Acid
Number of subjects: 151
Study 1702552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of Heparin (Kakkar protocol)
Number of subjects: 151
Study 1702552 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodilution
Number of subjects: 151
Study 7009254 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0
Study 7009254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31534374 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol compound supplementation (Vertigoval) for 60 days
Number of subjects: 258
Study 31534374 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 258
Study 28675566 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-fiber-oligosaccharide treatment group (n=11)
Number of subjects: 22
Study 28675566 — intervention group
Group type: COMPARATOR
Intervention: Glutamine F treatment group (n=11)
Number of subjects: 22
Study 25851721 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive medical education program (1h/day for 5 days) and specific drug therapy
Number of subjects: 76
Study 25851721 — intervention group
Group type: COMPARATOR
Intervention: Only drug therapy
Number of subjects: 76
Study 23453362 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial serum magnesium concentration >1.6 mg/dL
Number of subjects: 156
Study 23453362 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial serum magnesium concentration (median [IQ range])
Number of subjects: 156
Study 21084184 — intervention group
Group type: COMPARATOR
Intervention: Preoperative chemotherapy (CT) with cisplatin (80 mg/m(2)) and infusional 5 fluorouracil (1000 mg/m(2)/d) on days 1 and 21
Number of subjects: 75
Study 21084184 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy (CRT) with cisplatin (80 mg/m(2)), infusional 5 fluorouracil (800 mg/m(2)/d) starting on day 21, and radiation therapy (35 Gy in 15 fractions over 3 weeks)
Number of subjects: 75
Study 19833052 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (50 mg per day)
Number of subjects: 496
Study 19833052 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir (2000 mg per day)
Number of subjects: 496
Study 19833052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 496
Study 19833052 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir and Prednisolone
Number of subjects: 496
Study 19833052 — intervention group
Group type: COMPARATOR
Intervention: Placebo and Placebo
Number of subjects: 496
Study 17261397 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 73
Study 17261397 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 73
Study 17261397 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day)
Number of subjects: 73
Study 17261397 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day)
Number of subjects: 73
Study 17261397 — intervention group
Group type: COMPARATOR
Intervention: Control group (no statin treatment)
Number of subjects: 73
Study 15371775 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of 0.25% bupivacaine
Number of subjects: 0
Study 15371775 — intervention group
Group type: COMPARATOR
Intervention: Single dose caudal injection of 0.25% bupivacaine
Number of subjects: 0
Study 11345631 — intervention group
Group type: EXPERIMENTAL
Intervention: MR total spine imaging
Number of subjects: 50
Study 11345631 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without scoliosis)
Number of subjects: 50
Study 9510574 — intervention group
Group type: COMPARATOR
Intervention: Spiral CT
Number of subjects: 46
Study 9510574 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental CT
Number of subjects: 46
Study 7732541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride tablets administered since age 2
Number of subjects: 12
Study 7732541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine varnish and sealing of fissures with vitacryl
Number of subjects: 12
Study 3133708 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (150 mg daily)
Number of subjects: 227
Study 3133708 — intervention group
Group type: COMPARATOR
Intervention: Mianserin (30 mg for 7 days, then 60 mg daily)
Number of subjects: 227
Study 3133708 — intervention group
Group type: COMPARATOR
Intervention: Dothiepin (75 mg for 1 week, then 150 mg daily)
Number of subjects: 227
Study 3133708 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (75 mg for 1 week, then 100 mg daily)
Number of subjects: 227
Study 29903422 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily bladder irrigation with 450 cc sterile normal saline, in 3 150‐mL doses, for 3 consecutive days
Number of subjects: 100
Study 29903422 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bladder irrigation)
Number of subjects: 100
Study 29903422 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily bladder irrigation with normal saline
Number of subjects: 100
Study 27932360 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Exercise (HIFE) group
Number of subjects: 468
Study 27932360 — intervention group
Group type: COMPARATOR
Intervention: Individual physiotherapy sessions
Number of subjects: 468
Study 25483780 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered telephone support
Number of subjects: 189
Study 25483780 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered telephone counselling
Number of subjects: 189
Study 25483780 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 189
Study 24636287 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 0.5 mg/day
Number of subjects: 232
Study 21790238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubenimex capsule (30mg daily for 8 weeks)
Number of subjects: 63
Study 21790238 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ubenimex)
Number of subjects: 63
Study 19023743 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of judgment ability using various techniques
Number of subjects: 290
Study 19023743 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-ranked instruments for assessing judgment
Number of subjects: 290
Study 19023743 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in assessing judgment skills
Number of subjects: 290
Study 19023743 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived need for improved measures
Number of subjects: 290
Study 16582124 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 126
Study 16582124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 14742994 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab treatment in combination with tacrolimus and mycophenolate mofetil
Number of subjects: 46
Study 14742994 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated fractional excretion of sIL‐2Rα
Number of subjects: 46
Study 11393352 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte colony-stimulating factor (rHuG-CSF)
Number of subjects: 0
Study 11393352 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cyclic chemotherapy with rHuG-CSF
Number of subjects: 0
Study 11393352 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy with rHuG-CSF
Number of subjects: 0
Study 11393352 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuG-CSF with or without stem-cell support
Number of subjects: 0
Study 9003265 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose unfractionated heparin
Number of subjects: 53
Study 9003265 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 53
Study 9003265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic compression devices
Number of subjects: 53
Study 9003265 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot pumps with or without vena caval filters
Number of subjects: 53
Study 9003265 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPT score
Number of subjects: 53
Study 9003265 — intervention group
Group type: EXPERIMENTAL
Intervention: Color-flow duplex studies
Number of subjects: 53
Study 9003265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary angiograms
Number of subjects: 53
Study 7939756 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (150 mg/m2) followed by Doxorubicin (50 mg/m2)
Number of subjects: 12
Study 7939756 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (200 mg/m2) and Doxorubicin (75 mg/m2) alternating every 3 weeks
Number of subjects: 12
Study 7939756 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone and Doxorubicin alone
Number of subjects: 12
Study 3070520 — intervention group
Group type: EXPERIMENTAL
Intervention: DZ 15 mg
Number of subjects: 9
Study 3070520 — intervention group
Group type: EXPERIMENTAL
Intervention: DZ-CR 20 mg
Number of subjects: 9
Study 3070520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29896626 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 460
Study 29896626 — intervention group
Group type: COMPARATOR
Intervention: Standard Wound Management (Standard Dressings)
Number of subjects: 460
Study 26668177 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined estrogen plus progestin (0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate)
Number of subjects: 16608
Study 26668177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study 23278670 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg titanate
Number of subjects: 40
Study 23278670 — intervention group
Group type: COMPARATOR
Intervention: blasted Mg titanate
Number of subjects: 40
Study 23683558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative dobutamine infusion (3 μg/kg per minute or 5 μg/kg per minute)
Number of subjects: 60
Study 23683558 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 60
Study 20528283 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous Presentation Advertising (SPA)
Number of subjects: 0
Study 20528283 — intervention group
Group type: COMPARATOR
Intervention: Classical Sequential Advertising (CSA)
Number of subjects: 0
Study 17720609 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-strength training regime for the cervical flexor muscles
Number of subjects: 58
Study 17720609 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load training of the cranio-cervical flexor muscles
Number of subjects: 58
Study 16784917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SESs)
Number of subjects: 1510
Study 16784917 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMSs)
Number of subjects: 1510
Study 12944437 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with 70% N(2)O
Number of subjects: 30
Study 12944437 — intervention group
Group type: COMPARATOR
Intervention: Propofol with oxygen‐enriched air (FIO(2) = 0.3)
Number of subjects: 30
Study 10399801 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle reperfusion technique
Number of subjects: 14
Study 10399801 — intervention group
Group type: COMPARATOR
Intervention: Abrupt reperfusion
Number of subjects: 14
Study 10399801 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion after 20 min
Number of subjects: 14
Study 8533005 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (Plendil) 5 mg/day
Number of subjects: 797
Study 8533005 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of felodipine with other antihypertensive drugs (ACE inhibitors, beta blockers, diuretics)
Number of subjects: 797
Study 8533005 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of aspirin (75 mg/day)
Number of subjects: 797
Study 2677241 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 40
Study 2677241 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 40
Study 339282 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg 15‐methyl‐PGF2alpha‐methyl ester in a rapid releasing base, administered 6 hours prior to operation
Number of subjects: 60
Study 339282 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg 15‐methyl‐PGF2alpha‐methyl ester in a slow releasing base, administered 12 hours prior to operation
Number of subjects: 60
Study 339282 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 60
Study 31594481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Number of subjects: 317
Study 31594481 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of emotional expression
Number of subjects: 317
Study 31685618 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian misalignment
Number of subjects: 14
Study 28807486 — intervention group
Group type: EXPERIMENTAL
Intervention: Men living alone or divorced
Number of subjects: 1193
Study 28807486 — intervention group
Group type: COMPARATOR
Intervention: Men married
Number of subjects: 1193